ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 114 filers reported holding ACCELERON PHARMA INC in Q4 2014. The put-call ratio across all filers is 0.52 and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $24,574,000 | +6.0% | 142,783 | -22.7% | 0.01% | 0.0% |
| Q2 2021 | $23,193,000 | +36.1% | 184,815 | +47.0% | 0.01% | +25.0% |
| Q1 2021 | $17,046,000 | -3.7% | 125,695 | -9.1% | 0.00% | 0.0% |
| Q4 2020 | $17,696,000 | +35.0% | 138,313 | +18.8% | 0.00% | 0.0% |
| Q3 2020 | $13,107,000 | +130.7% | 116,472 | +95.3% | 0.00% | +100.0% |
| Q2 2020 | $5,682,000 | +68.0% | 59,646 | +58.5% | 0.00% | +100.0% |
| Q1 2020 | $3,382,000 | +32.7% | 37,641 | -21.7% | 0.00% | 0.0% |
| Q4 2019 | $2,548,000 | +76.0% | 48,069 | +31.1% | 0.00% | – |
| Q3 2019 | $1,448,000 | +4.9% | 36,673 | +9.2% | 0.00% | – |
| Q2 2019 | $1,380,000 | -16.0% | 33,590 | -4.7% | 0.00% | – |
| Q1 2019 | $1,642,000 | +11.8% | 35,259 | +4.5% | 0.00% | – |
| Q4 2018 | $1,469,000 | -28.5% | 33,735 | -6.0% | 0.00% | -100.0% |
| Q3 2018 | $2,055,000 | +17.6% | 35,899 | -0.3% | 0.00% | 0.0% |
| Q2 2018 | $1,747,000 | +28.9% | 36,001 | +3.9% | 0.00% | – |
| Q1 2018 | $1,355,000 | -4.3% | 34,653 | +3.9% | 0.00% | – |
| Q4 2017 | $1,416,000 | -12.3% | 33,366 | -22.8% | 0.00% | – |
| Q3 2017 | $1,614,000 | +39.9% | 43,244 | +13.8% | 0.00% | – |
| Q2 2017 | $1,154,000 | -45.2% | 37,997 | -52.2% | 0.00% | -100.0% |
| Q1 2017 | $2,104,000 | +114.0% | 79,462 | +106.1% | 0.00% | – |
| Q4 2016 | $983,000 | +16.7% | 38,552 | +65.8% | 0.00% | – |
| Q3 2016 | $842,000 | +5.5% | 23,258 | -1.0% | 0.00% | – |
| Q2 2016 | $798,000 | +26.7% | 23,483 | -1.8% | 0.00% | – |
| Q1 2016 | $630,000 | -46.7% | 23,917 | -1.4% | 0.00% | – |
| Q4 2015 | $1,183,000 | +630.2% | 24,264 | +272.9% | 0.00% | – |
| Q3 2015 | $162,000 | -18.2% | 6,506 | +4.3% | 0.00% | – |
| Q2 2015 | $198,000 | -30.3% | 6,240 | -16.3% | 0.00% | – |
| Q1 2015 | $284,000 | +330.3% | 7,456 | +340.7% | 0.00% | – |
| Q4 2014 | $66,000 | +69.2% | 1,692 | +30.9% | 0.00% | – |
| Q3 2014 | $39,000 | -37.1% | 1,293 | -28.4% | 0.00% | – |
| Q2 2014 | $62,000 | +121.4% | 1,806 | +123.5% | 0.00% | – |
| Q1 2014 | $28,000 | -56.2% | 808 | -49.6% | 0.00% | – |
| Q4 2013 | $64,000 | – | 1,604 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |